(Q78667340)
Statements
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial (English)
Choy EH
Garrood T
Farrow S
Ioannou Y
Bird H
Cheung N
Williams B
Hazleman B
Price R
Yoshizaki K
Nishimoto N
Kishimoto T
1 December 2002